Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pharmaxis Ltd (AU:SNT)
ASX:SNT
Holding AU:SNT?
Track your performance easily
SNT Stock Chart & Stats
Day’s RangeAU$0 - AU$0
52-Week RangeAU$0.01 - AU$0.06
Previous CloseAU$0.05
Volume128.72K
Average Volume (3M)1.89M
Market Cap
AU$64.60M
Enterprise ValueAU$58.52M
Total Cash (Recent Filing)AU$8.94M
Total Debt (Recent Filing)AU$4.29M
Price to Earnings (P/E)―
Beta2.20
Next Earnings
Feb 07, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares OutstandingN/A
10 Day Avg. Volume1,393,080
30 Day Avg. Volume1,887,967
Standard Deviation0.17
R-Squared0.03
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)13.13
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Pharmaxis Ltd News
PremiumCompany Announcements
Syntara Limited to Present Promising Cancer Trial Results
PremiumCompany Announcements
Pharmaxis Ltd Highlights Product Pipeline and Risks
PremiumCompany Announcements
Syntara Limited Advances Drug Trials and Financial Strategy
PremiumCompany Announcements
Pharmaxis Ltd: Positive Cash Flow Amidst Operating Losses
PremiumCompany Announcements
Syntara Limited to Host Investor Webinar on Drug Development Progress
PremiumCompany Announcements
Syntara Gains $4.56 Million to Boost Drug Development
PremiumCompany Announcements
Syntara Limited Announces Virtual Annual General MeetingPremiumCompany Announcements
Pharmaxis Ltd Reports Significant Shareholding ChangeOptions Prices
Currently, No data available
---
Ownership Overview
SNT FAQ
What was Pharmaxis Ltd’s price range in the past 12 months?
Pharmaxis Ltd lowest share price was AU$0.01 and its highest was AU$0.06 in the past 12 months.
What is Pharmaxis Ltd’s market cap?
Currently, no data Available
When is Pharmaxis Ltd’s upcoming earnings report date?
Pharmaxis Ltd’s upcoming earnings report date is Feb 07, 2025 which is in 72 days.
How were Pharmaxis Ltd’s earnings last quarter?
Pharmaxis Ltd released its earnings results on Aug 30, 2024. The company reported -AU$0.014 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.014.
Is Pharmaxis Ltd overvalued?
According to Wall Street analysts Pharmaxis Ltd’s price is currently Overvalued.
Does Pharmaxis Ltd pay dividends?
Pharmaxis Ltd does not currently pay dividends.
What is Pharmaxis Ltd’s EPS estimate?
Pharmaxis Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pharmaxis Ltd have?
Pharmaxis Ltd has 1,373,141,700 shares outstanding.
What happened to Pharmaxis Ltd’s price movement after its last earnings report?
Pharmaxis Ltd reported an EPS of -AU$0.014 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -25%.
Which hedge fund is a major shareholder of Pharmaxis Ltd?
Currently, no hedge funds are holding shares in AU:SNT
---
Pharmaxis Ltd Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:SNT Sentiment 90%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth AU$1.5M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
48.38%
12-Months-Change
Fundamentals
Return on Equity
-191.95%
Trailing 12-Months
Asset Growth
-56.79%
Trailing 12-Months
Company Description
Pharmaxis Ltd
Pharmaxis Ltd is an Australia based pharmaceutical research company engaged in the research, development, and commercialization of human healthcare products for the treatment and management of fibrotic and inflammatory diseases. The firm's research efforts are focused on discovering drugs to treat inflammatory and fibrotic diseases such as NASH, pulmonary fibrosis, kidney and liver fibrosis and cancer from its amine oxidase inhibitor chemistry platform. Its product pipeline also includes Orbital and ASM8. The operating segments are Mannitol respiratory business and New Drug Development. It generates maximum revenue from Mannitol respiratory business segment.
---
Technical Analysis
---